Catalyst Pharmaceutical Partners Launches New Website

Thu Feb 21, 2013 8:03am EST

* Reuters is not responsible for the content in this press release.

CORAL GABLES, Fla., Feb. 21, 2013 (GLOBE NEWSWIRE) -- Catalyst Pharmaceutical Partners, Inc.
(Nasdaq:CPRX), a specialty pharmaceutical company focused on the development and commercialization
of novel prescription drugs targeting rare (orphan) neurological diseases and disorders, is
pleased to announce the launch of its newly designed website. The site can be accessed at

"As we continue to make progress and further our plans for the transformation of Catalyst to a
company developing novel prescription drugs to treat rare neurological diseases, we felt that it
was important to upgrade and revamp our website," said Patrick J. McEnany, Chief Executive Officer
of Catalyst.

About the Website

The site provides an information platform for patients, physicians and investors in an easy to
navigate format.

The aim of the site is to allow visitors to gain a comprehensive understanding of the Company's
drug candidates. Patients and other interested parties can learn about Catalyst's drug candidates,
related clinical trials and the science behind them. Website visitors will have an ability to
follow the progress of the drug candidates and Company's development in the News and Events
sections. Current and potential investors will have the ability to download the latest information
on the Company in the Investors section.

In keeping with Catalyst's mission to provide treatment for rare neurological diseases through
collaboration with patients, physicians, scientists and other constituencies, the new website also
offers multiple ways of contacting the Company. All the inputs will be carefully reviewed and will
serve as a basis for further development of the website. The ultimate goal is to eventually expand
the website into a forum for patients, physicians and other stakeholders to share information,
ideas and recommendations.

About Catalyst Pharmaceutical Partners

Catalyst Pharmaceutical Partners, Inc., is a specialty pharmaceutical company focused on the
development and commercialization of prescription drugs targeting rare (orphan) neurological
diseases and disorders, including Lambert-Eaton Myasthenic Syndrome (LEMS), infantile spasms, and
Tourette's syndrome. Catalyst's lead candidate, FirdapseTM for the treatment of LEMS, is currently
undergoing testing in a global, multi-center, pivotal phase III trial. Catalyst is also developing
a potentially safer and more potent vigabatrin analog (designated CPP-115 by Catalyst) to treat
infantile spasms, and epilepsy, as well as other neurological conditions associated with reduced
GABAergic signaling, like post-traumatic stress disorder, Tourette's disorder, and movement
disorders associated with the treatment of Parkinson's Disease.

Forward-Looking Statements 

This press release contains forward-looking statements. Forward-looking statements involve known
and unknown risks and uncertainties, which may cause the Company's actual results in future
periods to differ materially from forecasted results. A number of factors, including whether any
of the Company's product candidates will ever be approved for commercialization and those factors
described in the Company's filings with the U.S. Securities and Exchange Commission (SEC), could
adversely affect the Company. Copies of the Company's filings with the SEC are available from the
SEC, may be found on the Company's website or may be obtained upon request from the Company. The
Company does not undertake any obligation to update the information contained herein, which speaks
only as of this date.

CONTACT: Patrick J. McEnany
         Catalyst Pharmaceutical Partners
         Chief Executive Officer
         (305) 529-2522
         Melody Carey
         Rx Communications Group
         (917) 322-2571